Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00234910 | Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients | PHASE3 | COMPLETED | 152 | — | — | Jan 1, 2005 | Jun 1, 2008 | Jul 10, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | 2 drug arm |
| B | ACTIVE_COMPARATOR | 3 drug arm, SOC |
| Name | Type | Description |
|---|---|---|
| Tenofovir DF | DRUG | TDF 300mg QD for 72 wks |
| lopinavir/ritonavir with 2 Nucleoside RTIs | DRUG | LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks |
Inclusion Criteria: * HIV positive * \>18 years of age * HIV RNA\> 400 copies/mL * Any CD 4 cell count * Antiretroviral naïve * No acute illness Exclusion Criteria: \-